Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials

Prostate cancer is the most frequent cancer in men and a leading cause of cancer death. Determining a patient’s optimal therapy is a challenge, where oncologists must select a therapy with the highest likelihood of success and the lowest likelihood of toxicity. International standards for prognostic...

Descripción completa

Detalles Bibliográficos
Autores principales: Esteva, Andre, Feng, Jean, van der Wal, Douwe, Huang, Shih-Cheng, Simko, Jeffry P., DeVries, Sandy, Chen, Emmalyn, Schaeffer, Edward M., Morgan, Todd M., Sun, Yilun, Ghorbani, Amirata, Naik, Nikhil, Nathawani, Dhruv, Socher, Richard, Michalski, Jeff M., Roach, Mack, Pisansky, Thomas M., Monson, Jedidiah M., Naz, Farah, Wallace, James, Ferguson, Michelle J., Bahary, Jean-Paul, Zou, James, Lungren, Matthew, Yeung, Serena, Ross, Ashley E., Sandler, Howard M., Tran, Phuoc T., Spratt, Daniel E., Pugh, Stephanie, Feng, Felix Y., Mohamad, Osama
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177850/
https://www.ncbi.nlm.nih.gov/pubmed/35676445
http://dx.doi.org/10.1038/s41746-022-00613-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177850/
https://www.ncbi.nlm.nih.gov/pubmed/35676445
http://dx.doi.org/10.1038/s41746-022-00613-w

Ejemplares similares